Research and Clinical Trials
Montefiore Einstein Center for Cancer Care physicians are on the leading edge of life-changing research. The partnership with our Albert Einstein College of Medicine has resulted in broad synergies and collaborations that advance clinical and translational research to accelerate the pace that new discoveries become the treatments and therapies that benefit patients.
Below is a sampling of our most recent research studies:
Advancements in Lung Cancer Care
February 1, 2017
Nitin Ohri, MD, Attending Physician, Radiation Oncology, Montefiore, and Assistant Professor, Radiation Oncology, Einstein and his research team recently concluded a study on pretreatment positron emission tomography as a tool for identifying lesions at risk for progression after concurrent chemoradiation therapy for locally advanced non-small cell lung cancer.
Exploring New Possibilities in Squamous Cell Carcinoma Treatment
January 9, 2017
Drs. Madhur Garg and Joseph Sparano led a team of researchers in a study to determine whether adding cetuximab to chemoradiation would reduce locoregional failure rates in squamous cell carcinoma of the anal canal.
Novel Biomarker Shows Promise in Early-stage Breast Cancer
December 12, 2016
Joseph A. Sparano, MD, Vice-Chairman, Medical Oncology, Montefiore Einstein Center for Cancer Care, discusses a study his team conducted which found that a biomarker for breast cancer metastasis was associated with cancer occurrence. The study analyzed tumors from 600 patients with early-stage breast cancer who had undergone surgery, adjuvant chemotherapy and endocrine therapy.
New Drug Combo Shows Promise Curbing Tough-to-Treat Breast Cancer
December 7, 2016
Noah S. Kornblum, MD, attending physician, Montefiore Einstein Center for Cancer Care, describes a phase II study his team presented at the San Antonio Breast Cancer Symposium that found a new drug combination can improve survival rates for people suffering from a common form of breast cancer. The treatment would help keep cancer at bay longer, from five months to 10 months, by reducing estrogen in the body and slowing cancer growth.
Interruption of Radiation Therapy Risks Cancer Recurrence
February 11, 2016
Madhur Garg, MD, clinical director and Nitin Ohri, MD, attending physician, Department of Radiation Oncology, Montefiore Einstein Center for Cancer Care, discuss a new study their team conducted that found missing two appointments of radiotherapy may impair tumor control, particularly for head and neck cancers. The findings demonstrated that noncompliance to scheduled appointments can pose a cancer recurrence risk. Noncompliance to scheduled treatments may also represent a new behavioral biomarker for identifying high-risk patients who require additional interventions to achieve optimal care outcomes.